Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
$9.67
-1.0%
$9.26
$6.38
$17.30
$940.40M1.421.22 million shs58,248 shs
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
$10.83
-0.2%
$6.44
$3.72
$12.61
$1.24B1.881.55 million shs215,446 shs
Oculis Holding AG stock logo
OCS
Oculis
$18.41
+0.1%
$18.97
$10.79
$23.08
$803.82M0.2945,211 shs5,330 shs
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
$1.89
-0.4%
$1.76
$0.77
$2.27
$189.08M2.311.76 million shs527,407 shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
+2.30%+9.47%-4.50%+27.21%-39.39%
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
+4.33%+42.48%+46.23%+154.69%+21.77%
Oculis Holding AG stock logo
OCS
Oculis
-0.16%-2.93%-7.02%+9.85%+64.29%
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
-0.26%-12.87%+23.05%+67.70%+63.36%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
2.7154 of 5 stars
3.53.00.00.01.91.70.6
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
2.6225 of 5 stars
4.41.00.00.02.50.00.6
Oculis Holding AG stock logo
OCS
Oculis
1.807 of 5 stars
3.53.00.00.00.60.00.6
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
0.3879 of 5 stars
0.01.00.00.01.81.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
3.00
Buy$18.1787.83% Upside
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
2.82
Moderate Buy$18.0066.25% Upside
Oculis Holding AG stock logo
OCS
Oculis
3.00
Buy$35.3391.92% Upside
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest SLS, AVDL, COGT, and OCS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/10/2025
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$25.00 ➝ $29.00
7/8/2025
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$12.00 ➝ $22.00
7/8/2025
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$17.00
7/8/2025
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$7.00 ➝ $9.00
7/7/2025
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$23.00 ➝ $28.00
7/7/2025
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$16.00 ➝ $18.00
6/30/2025
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral$10.00
6/17/2025
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
5/29/2025
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$21.00 ➝ $25.00
5/20/2025
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$14.00 ➝ $12.00
5/9/2025
Oculis Holding AG stock logo
OCS
Oculis
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$28.00 ➝ $33.00
(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
$194.45M4.81N/AN/A$0.77 per share12.56
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
N/AN/AN/AN/A$1.32 per shareN/A
Oculis Holding AG stock logo
OCS
Oculis
N/AN/AN/AN/A$1.91 per shareN/A
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
$1M188.28N/AN/A$0.13 per share14.52
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
-$48.83M-$0.27N/A161.20N/A-13.58%-36.07%-16.30%8/6/2025 (Estimated)
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
-$255.86M-$1.84N/AN/AN/AN/A-149.79%-75.61%8/5/2025 (Estimated)
Oculis Holding AG stock logo
OCS
Oculis
-$97.43M-$2.64N/AN/AN/A-13,788.70%-92.95%-70.03%8/26/2025 (Estimated)
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
-$30.88M-$0.38N/AN/AN/AN/A-193.67%-113.02%8/12/2025 (Estimated)

Latest SLS, AVDL, COGT, and OCS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2025Q2 2025
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
-$0.54N/AN/AN/AN/AN/A
5/13/2025Q1 2025
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
-$0.1067-$0.07+$0.0367-$0.07N/AN/A
5/8/2025Q1 2025
Oculis Holding AG stock logo
OCS
Oculis
-$0.51-$0.77-$0.26-$0.77$0.22 million$0.32 million
5/7/2025Q1 2025
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
-$0.07-$0.05+$0.02-$0.05$50.57 million$52.51 million
5/6/2025Q1 2025
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
-$0.56-$0.52+$0.04-$0.52N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
N/AN/AN/AN/AN/A
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
N/AN/AN/AN/AN/A
Oculis Holding AG stock logo
OCS
Oculis
N/AN/AN/AN/AN/A
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
N/A
2.73
2.33
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
N/A
5.13
5.13
Oculis Holding AG stock logo
OCS
Oculis
N/A
4.79
4.79
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
N/A
4.64
4.64

Institutional Ownership

CompanyInstitutional Ownership
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
69.19%
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
N/A
Oculis Holding AG stock logo
OCS
Oculis
22.30%
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
17.38%

Insider Ownership

CompanyInsider Ownership
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
5.20%
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
7.29%
Oculis Holding AG stock logo
OCS
Oculis
N/A
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
1.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Avadel Pharmaceuticals PLC. stock logo
AVDL
Avadel Pharmaceuticals
7096.74 million91.71 millionOptionable
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
80113.86 million105.56 millionOptionable
Oculis Holding AG stock logo
OCS
Oculis
243.66 millionN/ANot Optionable
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
1099.78 million98.38 millionNot Optionable

Recent News About These Companies

Sellas Life Sciences: Tons Of Completed Studies
SELLAS Life Sciences Group, Inc. Common Stock

New MarketBeat Followers Over Time

Media Sentiment Over Time

Avadel Pharmaceuticals stock logo

Avadel Pharmaceuticals NASDAQ:AVDL

$9.67 -0.10 (-1.00%)
As of 10:35 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Cogent Biosciences stock logo

Cogent Biosciences NASDAQ:COGT

$10.83 -0.02 (-0.21%)
As of 10:35 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Oculis stock logo

Oculis NASDAQ:OCS

$18.41 +0.01 (+0.05%)
As of 10:33 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.

SELLAS Life Sciences Group stock logo

SELLAS Life Sciences Group NASDAQ:SLS

$1.89 -0.01 (-0.42%)
As of 10:35 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.